Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 424 matching trials from the live ClinicalTrials.gov search.
Suspended Phase 1 Interventional Accepts healthy volunteers

Measuring Brain Inflammation in Autism

NCT03117530
Conditions
Autism Spectrum Disorder
Interventions
Minocycline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
Interferon, Rituxan and EPOCH, Tumor biopsy, Bone marrow biopsy, Bone marrow aspirate, Lumber puncture, CT, Brain MRI, Echocardiogram, FDG-PET
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Brain Peripheral Benzodiazepine Receptors

NCT00283920
Conditions
Healthy Volunteer
Interventions
[(11)C] PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Posterior Cortical Atrophy
Interventions
HD-tDCS sessions, Sham HD-tDCS sessions, HD-tDCS sessions - Open-label (after randomized treatment)
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

NCT02676843
Conditions
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies
Interventions
18F-AV-1451
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Epcoritamab, Magnetic Resonance Imaging, Polatuzumab Vedotin, Positron Emission Tomography, Prednisone, Rituximab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cocaine Use Disorder and Cortical Dopamine

NCT03349606
Conditions
Cocaine Dependence
Interventions
d-amphetamine, [C-11]FLB 457
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Recruiting Not applicable Interventional Accepts healthy volunteers

CW2IP2: Imaging and Diagnostic Assessments

NCT06083467
Conditions
Tauopathies
Interventions
Brain MRI Scan, Neurologic exam
Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid
Device · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Effect of Modulating Gamma Oscillations Using tACS

NCT03412604
Conditions
Alzheimer Disease
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma Multiforme, GBM
Interventions
18F-FET
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mild Traumatic Brain Injury
Interventions
[18F]PI-2620
Drug
Lead sponsor
Life Molecular Imaging SA.
Industry
Eligibility
25 Years to 54 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Conditions
Healthy
Interventions
[11C]JMJ-129-d2
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 105 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain Tumor
Interventions
FLT-PET scan
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

NCT00598390
Conditions
Healthy
Interventions
[11C]MePPEP
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Positron Emission Tomography to Measure Pain and Pain Control

NCT00001307
Conditions
Healthy, Hyperalgesia, Pain, Peripheral Nervous System Disease
Interventions
Oxygen-15 Water, Capsaicin
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
Interventions
Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
Drug · Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more